Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:21292365rdf:typepubmed:Citationlld:pubmed
pubmed-article:21292365lifeskim:mentionsumls-concept:C0013227lld:lifeskim
pubmed-article:21292365lifeskim:mentionsumls-concept:C0032659lld:lifeskim
pubmed-article:21292365lifeskim:mentionsumls-concept:C0332307lld:lifeskim
pubmed-article:21292365lifeskim:mentionsumls-concept:C0086045lld:lifeskim
pubmed-article:21292365lifeskim:mentionsumls-concept:C0332157lld:lifeskim
pubmed-article:21292365lifeskim:mentionsumls-concept:C0006560lld:lifeskim
pubmed-article:21292365lifeskim:mentionsumls-concept:C1512456lld:lifeskim
pubmed-article:21292365pubmed:issue8-9lld:pubmed
pubmed-article:21292365pubmed:dateCreated2011-6-13lld:pubmed
pubmed-article:21292365pubmed:abstractTextType 2 Diabetes (T2D) and particulate air pollution are associated with inflammatory dysregulation. We assessed the modifying effects of diabetes medications on the association of C-reactive protein (CRP), a marker of inflammation, and traffic exposure in adults with T2D (n = 379). CRP concentrations were significantly positively associated with residence ?100 m of a roadway, >100 m and ?200 m of a roadway and increased traffic density for individuals using insulin. For individuals using oral hypoglycemic medications (OHAs), CRP was significantly negatively associated with residence >100 m - ?200 m of a roadway and multiple roadway exposure in an interaction model. Among people with diabetes, individuals on insulin appear to be most vulnerable to the effects of traffic exposure. Disease severity among insulin users may promote the pro-inflammatory response to traffic exposure, though diabetes medications may also modify the response. Possible anti-inflammatory effects of OHAs with traffic exposure merit further evaluation.lld:pubmed
pubmed-article:21292365pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21292365pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21292365pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21292365pubmed:languageenglld:pubmed
pubmed-article:21292365pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21292365pubmed:citationSubsetIMlld:pubmed
pubmed-article:21292365pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21292365pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21292365pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21292365pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21292365pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21292365pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21292365pubmed:statusMEDLINElld:pubmed
pubmed-article:21292365pubmed:issn1873-6424lld:pubmed
pubmed-article:21292365pubmed:authorpubmed-author:TuckerKatheri...lld:pubmed
pubmed-article:21292365pubmed:authorpubmed-author:BruggeDougDlld:pubmed
pubmed-article:21292365pubmed:authorpubmed-author:GuteDavid MDMlld:pubmed
pubmed-article:21292365pubmed:authorpubmed-author:MwamburiMkaya...lld:pubmed
pubmed-article:21292365pubmed:authorpubmed-author:RiouxChristin...lld:pubmed
pubmed-article:21292365pubmed:copyrightInfoCopyright © 2010 Elsevier Ltd. All rights reserved.lld:pubmed
pubmed-article:21292365pubmed:issnTypeElectroniclld:pubmed
pubmed-article:21292365pubmed:volume159lld:pubmed
pubmed-article:21292365pubmed:ownerNLMlld:pubmed
pubmed-article:21292365pubmed:authorsCompleteYlld:pubmed
pubmed-article:21292365pubmed:pagination2051-60lld:pubmed
pubmed-article:21292365pubmed:dateRevised2011-11-17lld:pubmed
pubmed-article:21292365pubmed:meshHeadingpubmed-meshheading:21292365...lld:pubmed
pubmed-article:21292365pubmed:meshHeadingpubmed-meshheading:21292365...lld:pubmed
pubmed-article:21292365pubmed:meshHeadingpubmed-meshheading:21292365...lld:pubmed
pubmed-article:21292365pubmed:meshHeadingpubmed-meshheading:21292365...lld:pubmed
pubmed-article:21292365pubmed:meshHeadingpubmed-meshheading:21292365...lld:pubmed
pubmed-article:21292365pubmed:meshHeadingpubmed-meshheading:21292365...lld:pubmed
pubmed-article:21292365pubmed:meshHeadingpubmed-meshheading:21292365...lld:pubmed
pubmed-article:21292365pubmed:meshHeadingpubmed-meshheading:21292365...lld:pubmed
pubmed-article:21292365pubmed:meshHeadingpubmed-meshheading:21292365...lld:pubmed
pubmed-article:21292365pubmed:meshHeadingpubmed-meshheading:21292365...lld:pubmed
pubmed-article:21292365pubmed:meshHeadingpubmed-meshheading:21292365...lld:pubmed
pubmed-article:21292365pubmed:meshHeadingpubmed-meshheading:21292365...lld:pubmed
pubmed-article:21292365pubmed:meshHeadingpubmed-meshheading:21292365...lld:pubmed
pubmed-article:21292365pubmed:meshHeadingpubmed-meshheading:21292365...lld:pubmed
pubmed-article:21292365pubmed:meshHeadingpubmed-meshheading:21292365...lld:pubmed
pubmed-article:21292365pubmed:meshHeadingpubmed-meshheading:21292365...lld:pubmed
pubmed-article:21292365pubmed:meshHeadingpubmed-meshheading:21292365...lld:pubmed
pubmed-article:21292365pubmed:articleTitleTraffic exposure in a population with high prevalence type 2 diabetes--do medications influence concentrations of C-reactive protein?lld:pubmed
pubmed-article:21292365pubmed:affiliationDepartment of Public Health and Community Medicine, Tufts University, 136 Harrison Avenue, Boston, MA 02111, USA. christine.rioux@tufts.edulld:pubmed
pubmed-article:21292365pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:21292365pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
pubmed-article:21292365pubmed:publicationTypeResearch Support, N.I.H., Extramurallld:pubmed